{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:39:03Z","timestamp":1790854743373,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["468853597"],"award-info":[{"award-number":["468853597"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education Science Research and Technology Bonn Office","doi-asserted-by":"publisher","award":["01EE2303B"],"award-info":[{"award-number":["01EE2303B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008667","name":"Senshin Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008667","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.eclinm.2026.103847","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T20:19:35Z","timestamp":1774556375000},"page":"103847","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Antipsychotic dose and efficacy for acute schizophrenia spectrum disorders: an updated systematic review and dose-response meta-analysis"],"prefix":"10.1016","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1317-0220","authenticated-orcid":false,"given":"Yuki","family":"Furukawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rodolico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schneider-Thoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Priller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4934-4352","authenticated-orcid":false,"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8264-2039","authenticated-orcid":false,"given":"Spyridon","family":"Siafis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2026.103847_bib3","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1177\/02698811231205688","article-title":"Second international consensus study of antipsychotic dosing (ICSAD-2)","volume":"37","author":"McAdam","year":"2023","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.eclinm.2026.103847_bib4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/schbul\/sbac001","article-title":"Antipsychotic-induced weight gain: dose-response meta-analysis of randomized controlled trials","volume":"48","author":"Wu","year":"2022","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.eclinm.2026.103847_bib5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.euroneuro.2023.03.015","article-title":"Antipsychotic-induced akathisia in adults with acute schizophrenia: a systematic review and dose-response meta-analysis","volume":"72","author":"Wu","year":"2023","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.eclinm.2026.103847_bib6","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1038\/s41380-023-02203-y","article-title":"Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis","volume":"28","author":"Siafis","year":"2023","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.eclinm.2026.103847_bib7","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s40263-025-01218-z","article-title":"Antipsychotic-related prolactin changes: a systematic review and dose\u2013response meta-analysis","volume":"39","author":"Lin","year":"2025","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eclinm.2026.103847_bib8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.jcp.0000117422.05703.ae","article-title":"Dose response and dose equivalence of antipsychotics","volume":"24","author":"Davis","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.eclinm.2026.103847_bib9","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1176\/appi.ajp.2019.19010034","article-title":"Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia","volume":"177","author":"Leucht","year":"2020","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.eclinm.2026.103847_bib10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41537-021-00171-2","article-title":"Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials","volume":"7","author":"Sabe","year":"2021","journal-title":"NPJ Schizophr"},{"key":"10.1016\/j.eclinm.2026.103847_bib11","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1177\/0962280218773122","article-title":"One-stage dose\u2013response meta-analysis for aggregated data","volume":"28","author":"Crippa","year":"2019","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.eclinm.2026.103847_bib12","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/jamapsychiatry.2021.2130","article-title":"Examination of dosing of antipsychotic drugs for relapse prevention in patients with stable schizophrenia","volume":"78","author":"Leucht","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.eclinm.2026.103847_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.euroneuro.2025.02.012","article-title":"Antipsychotic drug dosing and study discontinuation in schizophrenia: a systematic review and dose-response meta-analysis","volume":"94","author":"Tian","year":"2025","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.eclinm.2026.103847_bib14","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2026.103847_bib15","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S2215-0366(19)30223-8","article-title":"Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis","volume":"6","author":"Schneider-Thoma","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.eclinm.2026.103847_bib16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.eclinm.2026.103847_bib17","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"key":"10.1016\/j.eclinm.2026.103847_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/schizbullopen\/sgaa061","article-title":"Cochrane schizophrenia group's study-based register of randomized controlled trials: development and content analysis","volume":"1","author":"Shokraneh","year":"2020","journal-title":"Schizophr Bull Open"},{"key":"10.1016\/j.eclinm.2026.103847_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2026.103847_bib20","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.103847_bib21","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2026.103847_bib22","doi-asserted-by":"crossref","first-page":"M22","DOI":"10.7326\/M22-1507","article-title":"The impact of the COVID-19 pandemic and associated control measures on the mental health of the general population","volume":"175","author":"Salanti","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eclinm.2026.103847_bib23","series-title":"R: A Language and Environment for Statistical Computing","year":"2020"},{"key":"10.1016\/j.eclinm.2026.103847_bib24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"\u00c9vid Based Ment Health"},{"key":"10.1016\/j.eclinm.2026.103847_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v072.c01","article-title":"Multivariate dose-response meta-analysis: the dosresmeta R package","volume":"72","author":"Crippa","year":"2016","journal-title":"J Stat Softw"},{"key":"10.1016\/j.eclinm.2026.103847_bib26","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"Am J Psychiatry"},{"issue":"8","key":"10.1016\/j.eclinm.2026.103847_bib27","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and reripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.103847_bib28","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline\u2013trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.103847_bib29","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and safety of xanomeline-trospium chloride in schizophrenia","volume":"81","author":"Kaul","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.eclinm.2026.103847_bib31","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/JCP.0b013e31817e63a5","article-title":"Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder","volume":"28","author":"Kinon","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.eclinm.2026.103847_bib32","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/JCP.0b013e3182214aad","article-title":"Dopamine D2 receptor occupancy and clinical effects","volume":"31","author":"Uchida","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.eclinm.2026.103847_bib33","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/JCP.0b013e3182983ffa","article-title":"Estimating dopamine D2 receptor occupancy for doses of 8 antipsychotics","volume":"33","author":"Lako","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.eclinm.2026.103847_bib30","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1001\/archpsyc.1992.01820050018002","article-title":"Haloperidol blood levels and clinical effects","volume":"49","author":"Volavka","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.eclinm.2026.103847_bib34","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/archpsyc.1995.03950220047010","article-title":"Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder","volume":"52","author":"Volavka","year":"1995","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.eclinm.2026.103847_bib35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1600-0447.1997.tb09642.x","article-title":"A two-phase, double-blind randomized study of three haloperidol plasma levels for acute psychosis with reassignment of initial non-responders","volume":"95","author":"Janicak","year":"1997","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.eclinm.2026.103847_bib37","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1017\/S0033291721004591","article-title":"Antipsychotic medication for women with schizophrenia spectrum disorders","volume":"52","author":"Brand","year":"2022","journal-title":"Psychol Med"},{"key":"10.1016\/j.eclinm.2026.103847_bib38","doi-asserted-by":"crossref","first-page":"967","DOI":"10.12688\/f1000research.169873.1","article-title":"Sex differences in the efficacy and tolerability of antipsychotic drugs in people with an acute exacerbation of schizophrenia: protocol for an individual-participant-data, dose-response, network meta-analysis","volume":"14","author":"Siafis","year":"2025","journal-title":"F1000Res"},{"key":"10.1016\/j.eclinm.2026.103847_bib39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.eclinm.2026.103847_bib40","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jamapsychiatry.2021.3990","article-title":"Representation and outcomes of individuals with schizophrenia seen in everyday practice who are ineligible for randomized clinical trials","volume":"79","author":"Taipale","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.eclinm.2026.103847_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/hex.70019","article-title":"Developing STEP-SE: a qualitative usability study of a novel patient-reported outcomes tool for managing side effects in shared decision-making for schizophrenia spectrum disorder care","volume":"27","author":"Rodolico","year":"2024","journal-title":"Health Expect"},{"key":"10.1016\/j.eclinm.2026.103847_bib41","series-title":"Analysis of Dose\u2013Response Studies\u2014Modeling Approaches","first-page":"146","author":"Pinheiro","year":"2006"},{"key":"10.1016\/j.eclinm.2026.103847_bib42","first-page":"CD011883","article-title":"Increasing antipsychotic dose for non response in schizophrenia","volume":"5","author":"Samara","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eclinm.2026.103847_bib43","first-page":"CD011885","article-title":"Switching antipsychotics versus continued current treatment in people with non-responsive schizophrenia","volume":"4","author":"Samara","year":"2025","journal-title":"Cochrane Database Syst Rev"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026000945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026000945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:07:59Z","timestamp":1778904479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026000945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":41,"alternative-id":["S2589537026000945"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103847","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antipsychotic dose and efficacy for acute schizophrenia spectrum disorders: an updated systematic review and dose-response meta-analysis","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103847","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103847"}}